PRP and exosomes. What the literature actually says.
A short, honest read on the two regenerative protocols patients ask about most: where the RCT evidence is real, where it is still emerging, and the maintenance schedule the literature actually supports.
What it is.
PRP — platelet-rich plasma — is the patient's own blood spun to concentrate platelets, then injected into the scalp in a 1-millilitre-per-injection grid. The biological rationale is that platelets release growth factors (PDGF, VEGF, IGF-1, EGF) that signal dermal-papilla cells and lengthen the anagen phase. Exosomes are nanoscale vesicles secreted by mesenchymal stem cells (commonly umbilical-cord or adipose-derived) that carry similar growth-factor cargo without the cells themselves.
The two are bundled in clinic menus because patients ask about them together, but the evidence base is asymmetric. PRP for androgenetic alopecia has been the subject of multiple RCTs and meta-analyses for over a decade. Exosomes have a much shorter publication history — most of it from 2023–2025 — and the regulatory framework is still being built. We treat the two protocols as related but not interchangeable.
The technique.
A trichologist or EBHRS-credentialed dermatologist examines the scalp under trichoscopy, scores Norwood or Ludwig pattern, and confirms the diagnosis is androgenetic alopecia before any injection is offered. Diffuse or scarring alopecia is not a PRP indication, and the consultation explicitly rules them out.
For PRP, 20–30 ml of venous blood is drawn, centrifuged in a closed-system kit (single-spin or double-spin protocol depending on the platelet concentration target), and the platelet-rich fraction is drawn into 1 ml syringes. Injections are placed at 1 cm intervals across the affected scalp, intradermal to subdermal depth, with a 30-gauge needle. The session takes 30–45 minutes. The literature converges on a 3-session induction at monthly intervals followed by maintenance every 3–6 months.
For exosomes, a commercially manufactured exosome solution (typically umbilical-cord mesenchymal-stem-cell-derived) is reconstituted at the bench and injected into the same grid pattern. The session takes 30 minutes. Manufacturing standards vary by supplier — Queen et al. (2025) flag this as the most important unresolved question in the category, which is why we use a single qualified supplier and disclose the source on the consent form.
What the outcomes data shows.
PRP has the stronger evidence base. Gupta et al. (2019, n=9 trials, 238 patients) reports a standardised mean difference in hair density of 0.58 (95% CI: 0.35–0.80) versus placebo at 3 and 6 months — a statistically significant effect of clinically meaningful size. Cruciani et al. (2023, Blood Transfusion) and Zhang et al. (2023, Journal of Cutaneous Medicine and Surgery) reach broadly consistent conclusions in their systematic reviews and meta-analyses. The 2024 PLOS ONE meta-analysis of PRP plus minoxidil versus minoxidil alone reports better outcomes for the combination in every included trial.
Exosomes are earlier in the evidence curve. Ersan et al. (2024, Aesthetic Plastic Surgery, n=30 male patients) is the most-cited prospective study and reports statistically significant hair-density gain at 4 and 12 weeks (p < 0.05) with no observed complications. The Queen et al. (2025) review of clinical studies in Dermatologic Surgery synthesises 9 studies and 125 patients, noting density gains of 9.5 to 35 hairs/cm² and thickness gains up to 13 µm — but with only two RCTs in the corpus.
Mesotherapy with dutasteride sits in a related but distinct category. Saceda-Corralo et al. (2022, Journal of Drugs in Dermatology) and Aledani et al. (2024, Cureus systematic review) describe outcomes that compare favourably to topical minoxidil. We mention this category because patients ask whether mesotherapy and PRP do the same thing — they don't. Mesotherapy delivers a pharmacological agent; PRP and exosomes deliver autologous or allogeneic signalling proteins.
What we still study.
Exosome therapy lacks the large randomised controlled trials that PRP has accumulated. Queen et al. (2025) explicitly call for larger well-designed trials with extended follow-up and consistent manufacturing standards before clinical claims firm up. The most honest summary is that exosomes are biologically plausible, early-evidence promising, and not yet proven to the standard PRP meets — and a clinic that markets exosomes as a superior alternative is overstating what is currently known.
Durability is the other open question. Both PRP and exosomes appear to require a maintenance schedule to hold density gains — the published data on what happens 18 to 24 months after a single induction course is thin, and most case series stop following patients at 12 months.
The Hektor protocol.
The standard induction is a 3-session PRP course at monthly intervals, with the optional addition of exosomes at session 1 and session 3 when the patient and clinician judge the cost-evidence trade-off acceptable. Trichoscopic photography under standardised lighting is taken at baseline and at 6 months.
Our 18% hair-density gain at 6 months is the mean change in trichoscopic hair count per cm² across 312 patients who completed the full induction course and returned for the 6-month review. It is in line with the published meta-analysis range (SMD 0.58 in Gupta 2019) and below the high end of optimistic single-arm exosome studies — which is the figure we choose to publish because it is the one we can audit.
- ·Confirmed androgenetic alopecia in men (Norwood 2–4) or women (Ludwig I–II), diagnosis stable
- ·Mild to moderate density loss where measurable trichoscopic baseline exists
- ·Patients already on topical minoxidil or finasteride who want adjunct support (PRP + minoxidil literature is the strongest)
- ·Post-transplant adjunct: stimulation of native hair around a recent graft area
- ·Patients seeking maintenance who prefer regenerative protocols over long-term pharmacology
- ·Healthy enough for a venous blood draw (PRP) and tolerant of intradermal injection
- —Active scarring alopecia (lichen planopilaris, frontal fibrosing alopecia) — these need dermatologic medical therapy first
- —Acute telogen effluvium or unresolved diffuse shed without an established underlying diagnosis
- —Pregnancy or breastfeeding
- —Anticoagulation that cannot be paused (PRP) or platelet disorders that compromise the spin product
- —Active scalp infection, severe eczema, or psoriasis at the injection sites
- —Unrealistic expectations of regrowing hair on a fully bald scalp — PRP and exosomes maintain and thicken existing follicles; they do not create new ones
Norwood 5–6 patients sometimes ask whether PRP could substitute for a transplant. The honest answer is no — regenerative therapies preserve and thicken existing follicles but do not generate new ones on an exhausted recipient zone. We have that conversation explicitly and route candidates toward Sapphire FUE or DHI if surgical restoration is what they actually need.
Exosome-only protocols (without PRP) sit in a thinner evidence band. Patients who specifically want exosomes — typically because they cannot have PRP for blood-draw reasons — are walked through the Queen (2025) review and told the protocol is supported by promising signal but only two RCTs. The decision is documented in the consent.
Recovery, by milestone.
Compared to alternatives.
Minoxidil is the pharmacological baseline with decades of RCT data. PRP plus minoxidil outperforms minoxidil alone in every included trial of the 2024 PLOS ONE meta-analysis. The honest framing is that PRP is an additive to minoxidil rather than a substitute — and that combining the two is the protocol with the strongest evidence base.PMID 10.1371/journal.pone.0308986
Oral 5-alpha-reductase inhibitors act on the hormonal driver of male-pattern hair loss and remain the most effective single intervention in the published literature for preserving existing hair. PRP and exosomes do not replace them; they layer on top. Patients tolerating finasteride benefit most from PRP as a thickening adjunct — not as a finasteride alternative.
Mesotherapy delivers a pharmacological agent (dutasteride) directly into the scalp, bypassing systemic absorption concerns. Outcomes compare favourably to topical minoxidil in real-world series. This is the pharmacological-injection comparator to the regenerative-injection category — different mechanism, partially overlapping use case. We do not currently offer mesotherapy in-house.PMID 35816059
Asymmetric evidence: PRP has the meta-analysis weight; exosomes have promising single-arm prospective studies and only two RCTs in the Queen (2025) corpus. The biologically plausible case for exosomes is real; the clinical-evidence case is still being built. We use PRP as the spine of the protocol and add exosomes selectively rather than substituting them.PMID 39447204
Different category entirely. Surgical restoration moves follicles from a permanent donor area to a thinning recipient area; PRP and exosomes signal existing follicles to lengthen anagen phase. A Norwood 5 with bald patches needs grafts, not signalling. PRP is appropriate alongside or after a transplant to support the native (non-transplanted) hair around it.
- ·Trichoscopic baseline + Norwood / Ludwig scoring by the EBHRS-credentialed dermatologist
- ·Blood work and venous draw (PRP sessions)
- ·Closed-system centrifuge processing with platelet-concentration quality check (PRP)
- ·Single-supplier umbilical-cord-MSC exosome solution with manufacturing-source disclosure (exosome sessions)
- ·30–45 minute injection session with intradermal grid placement
- ·Translator support (8 languages)
- ·6-month trichoscopic review against the baseline measurement
- ·Maintenance schedule planning at the 6-month review
The UK/US/EU figures are typical per-session benchmarks for clinics offering equivalent EBHRS-aligned protocols, not Hektor quotes. They are sourced from publicly published 2024–2025 clinic price pages. Exosomes price 1.5–3× above PRP in every market because the active material is a manufactured cell-derived product rather than a processed blood draw.
Our induction course is 3 PRP sessions at monthly intervals. Most patients should budget for the induction plus 2–3 maintenance sessions per year thereafter to hold density gains — the published evidence on density durability without maintenance is thin, so we plan for maintenance from the start rather than promise a one-and-done outcome.
Common questions.
Does PRP regrow hair on a bald scalp?+
How many sessions do I need to see results?+
Are exosomes better than PRP?+
Is there any downtime?+
Can I have PRP if I'm already on minoxidil or finasteride?+
Does PRP hurt?+
What source do your exosomes come from?+
Will PRP help if I just had a hair transplant?+
How long do the results last?+
Why is the cost in Istanbul lower than UK or US?+
Book this procedure.
A specialist-signed plan in 24 hours, with the bibliography for your specific candidacy attached. The deposit holds the day; the package is one number.
Book a day